A phase 2 clinical trial based on the dual HER2 blockade in CRC patients with HER2-positive tumors confirmed some clinical activity of this drug combination, with 4% of patients displaying a complete response and 26% a partial response to treatment [135]. Here, ERBB2 is linked to colorectal carcinoma.